NASDAQ:IMCR Immunocore (IMCR) Stock Price, News & Analysis $36.62 -0.13 (-0.35%) As of 08/28/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Immunocore Stock (NASDAQ:IMCR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immunocore alerts:Sign Up Key Stats Today's Range$36.05▼$36.7850-Day Range$29.20▼$37.4052-Week Range$27.56▼$40.71Volume300,326 shsAverage Volume433,175 shsMarket Capitalization$1.89 billionP/E RatioN/ADividend YieldN/APrice Target$56.38Consensus RatingModerate Buy Company Overview Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need. The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma. Beyond this, Immunocore’s pipeline includes multiple additional ImmTAC candidates in various stages of clinical evaluation across solid tumor indications such as colorectal, lung and other metastatic cancers. The firm also pursues collaborations with major biopharmaceutical partners to expand the reach and application of its TCR technology, notably with Genentech and Fosun Pharma. Headquartered in Oxford, England, with research and development facilities in Philadelphia, Pennsylvania, Immunocore leverages a global infrastructure to support its clinical trials and manufacturing efforts. Founded in 2008, the company is led by Chief Executive Officer Dr. Bahija Jallal, under whose direction Immunocore has advanced its first‐in‐class therapies from discovery through late‐stage clinical development. With a commitment to innovation in immune‐based medicine, Immunocore continues to explore new targets and indications that may benefit from the specificity and potency of its TCR‐based platform.AI Generated. May Contain Errors. Read More Immunocore Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreIMCR MarketRank™: Immunocore scored higher than 73% of companies evaluated by MarketBeat, and ranked 210th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingImmunocore has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 2 strong buy ratings, 6 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialImmunocore has a consensus price target of $56.38, representing about 53.9% upside from its current price of $36.62.Amount of Analyst CoverageImmunocore has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immunocore's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth316.67% Earnings GrowthEarnings for Immunocore are expected to grow by 316.67% in the coming year, from $0.06 to $0.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunocore is -98.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunocore is -98.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunocore has a P/B Ratio of 4.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunocore's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.05% of the float of Immunocore has been sold short.Short Interest Ratio / Days to CoverImmunocore has a short interest ratio ("days to cover") of 18.8, which indicates bearish sentiment.Change versus previous monthShort interest in Immunocore has recently decreased by 3.92%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunocore does not currently pay a dividend.Dividend GrowthImmunocore does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment1.00 News SentimentImmunocore has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Immunocore this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Immunocore to their MarketBeat watchlist in the last 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immunocore insiders have not sold or bought any company stock.Percentage Held by Insiders10.10% of the stock of Immunocore is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.50% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunocore's insider trading history. Receive IMCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMCR Stock News HeadlinesImmunocore (NASDAQ:IMCR) Upgraded at TD CowenAugust 27 at 1:43 AM | americanbankingnews.comJPMorgan Chase & Co. Begins Coverage on Immunocore (NASDAQ:IMCR)August 23, 2026 | americanbankingnews.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.August 30 at 1:00 AM | Profits Run (Ad)Immunocore outlines TEBE-AM data as early as end of 2026 while scaling KIMMTRAK beyond ~1,000 patients per yearAugust 7, 2026 | seekingalpha.comImmunocore Holdings plc 2026 Q2 - Results - Earnings Call PresentationAugust 7, 2026 | seekingalpha.comImmunocore Holdings PLC (IMCR) (Q2 2026) Earnings Call Highlights: Kimtrak Growth and Pipeline ...August 6, 2026 | finance.yahoo.comImmunocore Holdings plc (IMCR) Q2 2026 Earnings Call TranscriptAugust 6, 2026 | seekingalpha.comImmunocore to report second quarter 2026 financial results and host call on August 6, 2026July 30, 2026 | globenewswire.comSee More Headlines IMCR Stock Analysis - Frequently Asked Questions How have IMCR shares performed this year? Immunocore's stock was trading at $34.71 at the start of the year. Since then, IMCR shares have increased by 5.5% and is now trading at $36.62. How were Immunocore's earnings last quarter? Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) posted its quarterly earnings data on Friday, August, 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01. Immunocore had a negative net margin of 4.20% and a negative trailing twelve-month return on equity of 4.54%. Read the conference call transcript. When did Immunocore IPO? Immunocore (IMCR) raised $238 million in an initial public offering on Friday, February 5th 2021. The company issued 9,935,896 shares at $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies served as the underwriters for the IPO. Who are Immunocore's major shareholders? Immunocore's top institutional investors include Braidwell LP (1.02%), Public Employees Retirement System of Ohio (0.13%), Hennion & Walsh Asset Management Inc. (0.09%) and Headlands Technologies LLC (0.02%). Insiders that own company stock include Bros Advisors Lp Baker, Bahija Jallal, David M Berman, Leger Tina Amber St and John Goll. View institutional ownership trends. How do I buy shares of Immunocore? Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immunocore own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunocore investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings8/07/2026Today8/30/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 IMCR's financial health is in the Green zone, according to TradeSmith. IMCR has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMCR CIK1671927 Webwww.immunocore.com Phone44-12-3543-8600FaxN/AEmployees320Year Founded2008Price Target and Rating Average Price Target for Immunocore$56.38 High Price Target$100.00 Low Price Target$33.00 Potential Upside/Downside+53.9%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($0.37) Trailing P/E RatioN/A Forward P/E Ratio610.33 P/E GrowthN/ANet Income-$35.51 million Net Margins-4.20% Pretax Margin-0.63% Return on Equity-4.54% Return on Assets-1.66% Debt Debt-to-Equity Ratio0.94 Current Ratio4.47 Quick Ratio4.44 Sales & Book Value Annual Sales$430.78 million Price / Sales4.38 Cash FlowN/A Price / Cash FlowN/A Book Value$8.15 per share Price / Book4.49Miscellaneous Outstanding Shares51,499,000Free Float46,298,000Market Cap$1.89 billion OptionableOptionable Beta0.74 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:IMCR) was last updated on 8/30/2026 by MarketBeat.com Staff. From Our PartnersYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredNow that SpaceX is public, buy this ticker (no, not SpaceX or Tesla)The SpaceX IPO wasn't the big trade - according to Larry Benedict, founder of The Opportunistic Trader, it was...Brownstone Research | Sponsored23,281 stocks. Only ONE survived.One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...Monument Traders Alliance | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
